Provided by Tiger Fintech (Singapore) Pte. Ltd.

Shuttle Pharmaceuticals Inc

0.4111
-0.0089-2.12%
Post-market: 0.44990.0388+9.44%19:59 EDT
Volume:89.31K
Turnover:37.28K
Market Cap:2.57M
PE:-0.10
High:0.4323
Open:0.4200
Low:0.3910
Close:0.4200
Loading ...

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

THOMSON REUTERS
·
14 Mar

BRIEF-Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock

Reuters
·
05 Mar

Shuttle Pharmaceuticals Holdings Inc - Offering up to 10,000,000 Shares of Common Stock

THOMSON REUTERS
·
05 Mar

BRIEF-Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement

Reuters
·
01 Mar

Shuttle Pharmaceuticals Holdings Inc - Enters $2 Million Revolving Loan Agreement

THOMSON REUTERS
·
01 Mar

Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY

Benzinga
·
26 Feb

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

GlobeNewswire
·
26 Feb

Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine

TIPRANKS
·
21 Jan

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma

THOMSON REUTERS
·
21 Jan

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire
·
21 Jan

Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF

TIPRANKS
·
19 Dec 2024

Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance Psma Development Program

THOMSON REUTERS
·
19 Dec 2024

Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

GlobeNewswire
·
19 Dec 2024

Shuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line

TIPRANKS
·
26 Nov 2024

BRIEF-Shuttle Pharma Expands Patient Enrollment For Phase 2 Clinical Trial

Reuters
·
26 Nov 2024

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as Uva Cancer Center Doses Its First Patient

THOMSON REUTERS
·
26 Nov 2024